nodes	percent_of_prediction	percent_of_DWPC	metapath
Pralatrexate—SLC19A1—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	0.00714	0.0581	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—BARD1—peripheral nervous system neoplasm	0.00611	0.0497	CbGpPWpGaD
Pralatrexate—FPGS—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	0.00607	0.0494	CbGpPWpGaD
Pralatrexate—TYMS—Vitamin A—Isotretinoin—peripheral nervous system neoplasm	0.00577	0.134	CbGdCrCtD
Pralatrexate—TYMS—Vitamin A—Tretinoin—peripheral nervous system neoplasm	0.00577	0.134	CbGdCrCtD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—BARD1—peripheral nervous system neoplasm	0.00533	0.0434	CbGpPWpGaD
Pralatrexate—TYMS—Nucleotide metabolism—NME1—peripheral nervous system neoplasm	0.00474	0.0386	CbGpPWpGaD
Pralatrexate—Toxic epidermal necrolysis—Alitretinoin—peripheral nervous system neoplasm	0.00467	0.00559	CcSEcCtD
Pralatrexate—Dehydration—Vincristine—peripheral nervous system neoplasm	0.00464	0.00557	CcSEcCtD
Pralatrexate—Pancytopenia—Dactinomycin—peripheral nervous system neoplasm	0.00459	0.0055	CcSEcCtD
Pralatrexate—Neutropenia—Dactinomycin—peripheral nervous system neoplasm	0.00452	0.00542	CcSEcCtD
Pralatrexate—TYMS—Vitamin A—Alitretinoin—peripheral nervous system neoplasm	0.00437	0.102	CbGdCrCtD
Pralatrexate—Neutropenia—Alitretinoin—peripheral nervous system neoplasm	0.00419	0.00502	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Alitretinoin—peripheral nervous system neoplasm	0.00416	0.00499	CcSEcCtD
Pralatrexate—Dehydration—Cisplatin—peripheral nervous system neoplasm	0.00411	0.00492	CcSEcCtD
Pralatrexate—Pancytopenia—Vincristine—peripheral nervous system neoplasm	0.0041	0.00491	CcSEcCtD
Pralatrexate—Neutropenia—Vincristine—peripheral nervous system neoplasm	0.00404	0.00484	CcSEcCtD
Pralatrexate—TYMS—Alitretinoin—Tretinoin—peripheral nervous system neoplasm	0.00403	0.0937	CbGdCrCtD
Pralatrexate—TYMS—Isotretinoin—Tretinoin—peripheral nervous system neoplasm	0.00403	0.0937	CbGdCrCtD
Pralatrexate—TYMS—Tretinoin—Isotretinoin—peripheral nervous system neoplasm	0.00403	0.0937	CbGdCrCtD
Pralatrexate—TYMS—Alitretinoin—Isotretinoin—peripheral nervous system neoplasm	0.00403	0.0937	CbGdCrCtD
Pralatrexate—Hypokalaemia—Cisplatin—peripheral nervous system neoplasm	0.00402	0.00482	CcSEcCtD
Pralatrexate—Back pain—Topotecan—peripheral nervous system neoplasm	0.00402	0.00481	CcSEcCtD
Pralatrexate—Back pain—Tretinoin—peripheral nervous system neoplasm	0.00398	0.00478	CcSEcCtD
Pralatrexate—Back pain—Isotretinoin—peripheral nervous system neoplasm	0.00398	0.00478	CcSEcCtD
Pralatrexate—Anaemia—Topotecan—peripheral nervous system neoplasm	0.00384	0.0046	CcSEcCtD
Pralatrexate—Anaemia—Tretinoin—peripheral nervous system neoplasm	0.00381	0.00456	CcSEcCtD
Pralatrexate—Anaemia—Isotretinoin—peripheral nervous system neoplasm	0.00381	0.00456	CcSEcCtD
Pralatrexate—Epistaxis—Alitretinoin—peripheral nervous system neoplasm	0.00377	0.00452	CcSEcCtD
Pralatrexate—Anaemia—Melphalan—peripheral nervous system neoplasm	0.00376	0.0045	CcSEcCtD
Pralatrexate—Leukopenia—Topotecan—peripheral nervous system neoplasm	0.00372	0.00445	CcSEcCtD
Pralatrexate—Neoplasm malignant—Epirubicin—peripheral nervous system neoplasm	0.00366	0.00439	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Etoposide—peripheral nervous system neoplasm	0.00364	0.00437	CcSEcCtD
Pralatrexate—Leukopenia—Melphalan—peripheral nervous system neoplasm	0.00364	0.00436	CcSEcCtD
Pralatrexate—Pancytopenia—Cisplatin—peripheral nervous system neoplasm	0.00362	0.00434	CcSEcCtD
Pralatrexate—Cough—Topotecan—peripheral nervous system neoplasm	0.00362	0.00434	CcSEcCtD
Pralatrexate—Cough—Tretinoin—peripheral nervous system neoplasm	0.00359	0.00431	CcSEcCtD
Pralatrexate—Cough—Isotretinoin—peripheral nervous system neoplasm	0.00359	0.00431	CcSEcCtD
Pralatrexate—Cough—Melphalan—peripheral nervous system neoplasm	0.00355	0.00425	CcSEcCtD
Pralatrexate—FPGS—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.00339	0.0276	CbGpPWpGaD
Pralatrexate—Neoplasm malignant—Doxorubicin—peripheral nervous system neoplasm	0.00338	0.00406	CcSEcCtD
Pralatrexate—Oedema—Tretinoin—peripheral nervous system neoplasm	0.00336	0.00403	CcSEcCtD
Pralatrexate—Oedema—Isotretinoin—peripheral nervous system neoplasm	0.00336	0.00403	CcSEcCtD
Pralatrexate—Pancytopenia—Etoposide—peripheral nervous system neoplasm	0.00332	0.00398	CcSEcCtD
Pralatrexate—Oedema—Melphalan—peripheral nervous system neoplasm	0.00332	0.00398	CcSEcCtD
Pralatrexate—Thrombocytopenia—Topotecan—peripheral nervous system neoplasm	0.00332	0.00398	CcSEcCtD
Pralatrexate—Thrombocytopenia—Isotretinoin—peripheral nervous system neoplasm	0.00329	0.00394	CcSEcCtD
Pralatrexate—Thrombocytopenia—Tretinoin—peripheral nervous system neoplasm	0.00329	0.00394	CcSEcCtD
Pralatrexate—Tachycardia—Tretinoin—peripheral nervous system neoplasm	0.00328	0.00393	CcSEcCtD
Pralatrexate—Tachycardia—Isotretinoin—peripheral nervous system neoplasm	0.00328	0.00393	CcSEcCtD
Pralatrexate—Neutropenia—Etoposide—peripheral nervous system neoplasm	0.00327	0.00392	CcSEcCtD
Pralatrexate—Thrombocytopenia—Melphalan—peripheral nervous system neoplasm	0.00325	0.00389	CcSEcCtD
Pralatrexate—Tachycardia—Melphalan—peripheral nervous system neoplasm	0.00324	0.00388	CcSEcCtD
Pralatrexate—Anorexia—Topotecan—peripheral nervous system neoplasm	0.00323	0.00387	CcSEcCtD
Pralatrexate—Anorexia—Tretinoin—peripheral nervous system neoplasm	0.0032	0.00384	CcSEcCtD
Pralatrexate—Anorexia—Isotretinoin—peripheral nervous system neoplasm	0.0032	0.00384	CcSEcCtD
Pralatrexate—Anorexia—Melphalan—peripheral nervous system neoplasm	0.00316	0.00379	CcSEcCtD
Pralatrexate—Anaemia—Dactinomycin—peripheral nervous system neoplasm	0.00311	0.00373	CcSEcCtD
Pralatrexate—TYMS—Tretinoin—Alitretinoin—peripheral nervous system neoplasm	0.00306	0.071	CbGdCrCtD
Pralatrexate—TYMS—Isotretinoin—Alitretinoin—peripheral nervous system neoplasm	0.00306	0.071	CbGdCrCtD
Pralatrexate—Dyspnoea—Topotecan—peripheral nervous system neoplasm	0.00302	0.00362	CcSEcCtD
Pralatrexate—Back pain—Alitretinoin—peripheral nervous system neoplasm	0.00302	0.00362	CcSEcCtD
Pralatrexate—Leukopenia—Dactinomycin—peripheral nervous system neoplasm	0.00301	0.00361	CcSEcCtD
Pralatrexate—Dyspnoea—Tretinoin—peripheral nervous system neoplasm	0.003	0.00359	CcSEcCtD
Pralatrexate—Dyspnoea—Isotretinoin—peripheral nervous system neoplasm	0.003	0.00359	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00297	0.0242	CbGpPWpGaD
Pralatrexate—Dyspnoea—Melphalan—peripheral nervous system neoplasm	0.00296	0.00355	CcSEcCtD
Pralatrexate—Decreased appetite—Topotecan—peripheral nervous system neoplasm	0.00294	0.00353	CcSEcCtD
Pralatrexate—Decreased appetite—Isotretinoin—peripheral nervous system neoplasm	0.00292	0.0035	CcSEcCtD
Pralatrexate—Decreased appetite—Tretinoin—peripheral nervous system neoplasm	0.00292	0.0035	CcSEcCtD
Pralatrexate—Fatigue—Topotecan—peripheral nervous system neoplasm	0.00292	0.0035	CcSEcCtD
Pralatrexate—Back pain—Vincristine—peripheral nervous system neoplasm	0.00291	0.00349	CcSEcCtD
Pralatrexate—Fatigue—Tretinoin—peripheral nervous system neoplasm	0.0029	0.00347	CcSEcCtD
Pralatrexate—Fatigue—Isotretinoin—peripheral nervous system neoplasm	0.0029	0.00347	CcSEcCtD
Pralatrexate—Constipation—Topotecan—peripheral nervous system neoplasm	0.0029	0.00347	CcSEcCtD
Pralatrexate—Anaemia—Alitretinoin—peripheral nervous system neoplasm	0.00288	0.00346	CcSEcCtD
Pralatrexate—Decreased appetite—Melphalan—peripheral nervous system neoplasm	0.00288	0.00346	CcSEcCtD
Pralatrexate—Constipation—Tretinoin—peripheral nervous system neoplasm	0.00287	0.00345	CcSEcCtD
Pralatrexate—Constipation—Isotretinoin—peripheral nervous system neoplasm	0.00287	0.00345	CcSEcCtD
Pralatrexate—Fatigue—Melphalan—peripheral nervous system neoplasm	0.00286	0.00343	CcSEcCtD
Pralatrexate—Anaemia—Vincristine—peripheral nervous system neoplasm	0.00278	0.00333	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Topotecan—peripheral nervous system neoplasm	0.00277	0.00332	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Isotretinoin—peripheral nervous system neoplasm	0.00275	0.00329	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Tretinoin—peripheral nervous system neoplasm	0.00275	0.00329	CcSEcCtD
Pralatrexate—Oedema—Dactinomycin—peripheral nervous system neoplasm	0.00275	0.00329	CcSEcCtD
Pralatrexate—Cough—Alitretinoin—peripheral nervous system neoplasm	0.00272	0.00326	CcSEcCtD
Pralatrexate—Sepsis—Epirubicin—peripheral nervous system neoplasm	0.00271	0.00325	CcSEcCtD
Pralatrexate—Leukopenia—Vincristine—peripheral nervous system neoplasm	0.00269	0.00323	CcSEcCtD
Pralatrexate—Thrombocytopenia—Dactinomycin—peripheral nervous system neoplasm	0.00269	0.00322	CcSEcCtD
Pralatrexate—DHFR—Tetrahydrobiopterin (BH4) synthesis, recycling, salvage and regulation—AKT1—peripheral nervous system neoplasm	0.00269	0.0219	CbGpPWpGaD
Pralatrexate—Body temperature increased—Topotecan—peripheral nervous system neoplasm	0.00268	0.00321	CcSEcCtD
Pralatrexate—Abdominal pain—Topotecan—peripheral nervous system neoplasm	0.00268	0.00321	CcSEcCtD
Pralatrexate—Body temperature increased—Isotretinoin—peripheral nervous system neoplasm	0.00266	0.00319	CcSEcCtD
Pralatrexate—Body temperature increased—Tretinoin—peripheral nervous system neoplasm	0.00266	0.00319	CcSEcCtD
Pralatrexate—Abdominal pain—Isotretinoin—peripheral nervous system neoplasm	0.00266	0.00319	CcSEcCtD
Pralatrexate—Abdominal pain—Tretinoin—peripheral nervous system neoplasm	0.00266	0.00319	CcSEcCtD
Pralatrexate—Anorexia—Dactinomycin—peripheral nervous system neoplasm	0.00262	0.00314	CcSEcCtD
Pralatrexate—Oedema—Alitretinoin—peripheral nervous system neoplasm	0.00255	0.00305	CcSEcCtD
Pralatrexate—DHFR—Defective AMN causes hereditary megaloblastic anemia 1—SLC2A1—peripheral nervous system neoplasm	0.00254	0.0207	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00253	0.0206	CbGpPWpGaD
Pralatrexate—Sepsis—Doxorubicin—peripheral nervous system neoplasm	0.00251	0.00301	CcSEcCtD
Pralatrexate—Thrombocytopenia—Alitretinoin—peripheral nervous system neoplasm	0.00249	0.00299	CcSEcCtD
Pralatrexate—Tachycardia—Alitretinoin—peripheral nervous system neoplasm	0.00249	0.00298	CcSEcCtD
Pralatrexate—Anaemia—Cisplatin—peripheral nervous system neoplasm	0.00246	0.00295	CcSEcCtD
Pralatrexate—Oedema—Vincristine—peripheral nervous system neoplasm	0.00245	0.00294	CcSEcCtD
Pralatrexate—Asthenia—Topotecan—peripheral nervous system neoplasm	0.00243	0.00291	CcSEcCtD
Pralatrexate—Anorexia—Alitretinoin—peripheral nervous system neoplasm	0.00243	0.00291	CcSEcCtD
Pralatrexate—Asthenia—Tretinoin—peripheral nervous system neoplasm	0.00241	0.00289	CcSEcCtD
Pralatrexate—Asthenia—Isotretinoin—peripheral nervous system neoplasm	0.00241	0.00289	CcSEcCtD
Pralatrexate—Thrombocytopenia—Vincristine—peripheral nervous system neoplasm	0.0024	0.00288	CcSEcCtD
Pralatrexate—Pruritus—Topotecan—peripheral nervous system neoplasm	0.0024	0.00287	CcSEcCtD
Pralatrexate—Decreased appetite—Dactinomycin—peripheral nervous system neoplasm	0.00239	0.00286	CcSEcCtD
Pralatrexate—Leukopenia—Cisplatin—peripheral nervous system neoplasm	0.00238	0.00285	CcSEcCtD
Pralatrexate—Asthenia—Melphalan—peripheral nervous system neoplasm	0.00238	0.00285	CcSEcCtD
Pralatrexate—Pruritus—Isotretinoin—peripheral nervous system neoplasm	0.00238	0.00285	CcSEcCtD
Pralatrexate—Pruritus—Tretinoin—peripheral nervous system neoplasm	0.00238	0.00285	CcSEcCtD
Pralatrexate—Fatigue—Dactinomycin—peripheral nervous system neoplasm	0.00237	0.00284	CcSEcCtD
Pralatrexate—Back pain—Etoposide—peripheral nervous system neoplasm	0.00236	0.00282	CcSEcCtD
Pralatrexate—Pruritus—Melphalan—peripheral nervous system neoplasm	0.00235	0.00281	CcSEcCtD
Pralatrexate—Anorexia—Vincristine—peripheral nervous system neoplasm	0.00234	0.0028	CcSEcCtD
Pralatrexate—Diarrhoea—Topotecan—peripheral nervous system neoplasm	0.00232	0.00278	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—NME1—peripheral nervous system neoplasm	0.00232	0.0189	CbGpPWpGaD
Pralatrexate—Diarrhoea—Isotretinoin—peripheral nervous system neoplasm	0.0023	0.00276	CcSEcCtD
Pralatrexate—Diarrhoea—Tretinoin—peripheral nervous system neoplasm	0.0023	0.00276	CcSEcCtD
Pralatrexate—SLC19A1—Folate Metabolism—TP53—peripheral nervous system neoplasm	0.00229	0.0187	CbGpPWpGaD
Pralatrexate—Dyspnoea—Alitretinoin—peripheral nervous system neoplasm	0.00227	0.00272	CcSEcCtD
Pralatrexate—Diarrhoea—Melphalan—peripheral nervous system neoplasm	0.00227	0.00272	CcSEcCtD
Pralatrexate—Pain in extremity—Epirubicin—peripheral nervous system neoplasm	0.00227	0.00272	CcSEcCtD
Pralatrexate—Anaemia—Etoposide—peripheral nervous system neoplasm	0.00225	0.0027	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Dactinomycin—peripheral nervous system neoplasm	0.00225	0.00269	CcSEcCtD
Pralatrexate—Decreased appetite—Alitretinoin—peripheral nervous system neoplasm	0.00221	0.00265	CcSEcCtD
Pralatrexate—Fatigue—Alitretinoin—peripheral nervous system neoplasm	0.0022	0.00263	CcSEcCtD
Pralatrexate—Leukopenia—Etoposide—peripheral nervous system neoplasm	0.00218	0.00261	CcSEcCtD
Pralatrexate—Constipation—Alitretinoin—peripheral nervous system neoplasm	0.00218	0.00261	CcSEcCtD
Pralatrexate—Body temperature increased—Dactinomycin—peripheral nervous system neoplasm	0.00217	0.0026	CcSEcCtD
Pralatrexate—Abdominal pain—Dactinomycin—peripheral nervous system neoplasm	0.00217	0.0026	CcSEcCtD
Pralatrexate—Oedema—Cisplatin—peripheral nervous system neoplasm	0.00217	0.0026	CcSEcCtD
Pralatrexate—Vomiting—Topotecan—peripheral nervous system neoplasm	0.00215	0.00258	CcSEcCtD
Pralatrexate—Vomiting—Isotretinoin—peripheral nervous system neoplasm	0.00214	0.00256	CcSEcCtD
Pralatrexate—Vomiting—Tretinoin—peripheral nervous system neoplasm	0.00214	0.00256	CcSEcCtD
Pralatrexate—Rash—Topotecan—peripheral nervous system neoplasm	0.00214	0.00256	CcSEcCtD
Pralatrexate—Dermatitis—Topotecan—peripheral nervous system neoplasm	0.00213	0.00256	CcSEcCtD
Pralatrexate—Decreased appetite—Vincristine—peripheral nervous system neoplasm	0.00213	0.00256	CcSEcCtD
Pralatrexate—Cough—Etoposide—peripheral nervous system neoplasm	0.00213	0.00255	CcSEcCtD
Pralatrexate—Thrombocytopenia—Cisplatin—peripheral nervous system neoplasm	0.00212	0.00255	CcSEcCtD
Pralatrexate—Rash—Tretinoin—peripheral nervous system neoplasm	0.00212	0.00254	CcSEcCtD
Pralatrexate—Rash—Isotretinoin—peripheral nervous system neoplasm	0.00212	0.00254	CcSEcCtD
Pralatrexate—Tachycardia—Cisplatin—peripheral nervous system neoplasm	0.00212	0.00254	CcSEcCtD
Pralatrexate—Dermatitis—Tretinoin—peripheral nervous system neoplasm	0.00212	0.00254	CcSEcCtD
Pralatrexate—Dermatitis—Isotretinoin—peripheral nervous system neoplasm	0.00212	0.00254	CcSEcCtD
Pralatrexate—Fatigue—Vincristine—peripheral nervous system neoplasm	0.00212	0.00254	CcSEcCtD
Pralatrexate—Vomiting—Melphalan—peripheral nervous system neoplasm	0.00211	0.00253	CcSEcCtD
Pralatrexate—Dehydration—Epirubicin—peripheral nervous system neoplasm	0.00211	0.00253	CcSEcCtD
Pralatrexate—Constipation—Vincristine—peripheral nervous system neoplasm	0.0021	0.00252	CcSEcCtD
Pralatrexate—Pain in extremity—Doxorubicin—peripheral nervous system neoplasm	0.0021	0.00252	CcSEcCtD
Pralatrexate—Liver function test abnormal—Epirubicin—peripheral nervous system neoplasm	0.00209	0.00251	CcSEcCtD
Pralatrexate—Rash—Melphalan—peripheral nervous system neoplasm	0.00209	0.00251	CcSEcCtD
Pralatrexate—Dermatitis—Melphalan—peripheral nervous system neoplasm	0.00209	0.00251	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Alitretinoin—peripheral nervous system neoplasm	0.00208	0.0025	CcSEcCtD
Pralatrexate—Anorexia—Cisplatin—peripheral nervous system neoplasm	0.00207	0.00248	CcSEcCtD
Pralatrexate—Hypokalaemia—Epirubicin—peripheral nervous system neoplasm	0.00206	0.00247	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Epirubicin—peripheral nervous system neoplasm	0.00204	0.00245	CcSEcCtD
Pralatrexate—Abdominal pain—Alitretinoin—peripheral nervous system neoplasm	0.00201	0.00241	CcSEcCtD
Pralatrexate—Body temperature increased—Alitretinoin—peripheral nervous system neoplasm	0.00201	0.00241	CcSEcCtD
Pralatrexate—Nausea—Topotecan—peripheral nervous system neoplasm	0.00201	0.00241	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Vincristine—peripheral nervous system neoplasm	0.00201	0.00241	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00201	0.0163	CbGpPWpGaD
Pralatrexate—Nausea—Isotretinoin—peripheral nervous system neoplasm	0.002	0.00239	CcSEcCtD
Pralatrexate—Nausea—Tretinoin—peripheral nervous system neoplasm	0.002	0.00239	CcSEcCtD
Pralatrexate—Asthenia—Dactinomycin—peripheral nervous system neoplasm	0.00197	0.00236	CcSEcCtD
Pralatrexate—Nausea—Melphalan—peripheral nervous system neoplasm	0.00197	0.00236	CcSEcCtD
Pralatrexate—Dehydration—Doxorubicin—peripheral nervous system neoplasm	0.00195	0.00234	CcSEcCtD
Pralatrexate—Thrombocytopenia—Etoposide—peripheral nervous system neoplasm	0.00195	0.00233	CcSEcCtD
Pralatrexate—Tachycardia—Etoposide—peripheral nervous system neoplasm	0.00194	0.00233	CcSEcCtD
Pralatrexate—Body temperature increased—Vincristine—peripheral nervous system neoplasm	0.00194	0.00233	CcSEcCtD
Pralatrexate—Abdominal pain—Vincristine—peripheral nervous system neoplasm	0.00194	0.00233	CcSEcCtD
Pralatrexate—Liver function test abnormal—Doxorubicin—peripheral nervous system neoplasm	0.00194	0.00232	CcSEcCtD
Pralatrexate—Dyspnoea—Cisplatin—peripheral nervous system neoplasm	0.00193	0.00232	CcSEcCtD
Pralatrexate—Hypokalaemia—Doxorubicin—peripheral nervous system neoplasm	0.00191	0.00229	CcSEcCtD
Pralatrexate—Anorexia—Etoposide—peripheral nervous system neoplasm	0.0019	0.00227	CcSEcCtD
Pralatrexate—Toxic epidermal necrolysis—Doxorubicin—peripheral nervous system neoplasm	0.00189	0.00226	CcSEcCtD
Pralatrexate—Decreased appetite—Cisplatin—peripheral nervous system neoplasm	0.00189	0.00226	CcSEcCtD
Pralatrexate—Diarrhoea—Dactinomycin—peripheral nervous system neoplasm	0.00188	0.00225	CcSEcCtD
Pralatrexate—DHFR—Metabolism of nitric oxide—AKT1—peripheral nervous system neoplasm	0.00186	0.0151	CbGpPWpGaD
Pralatrexate—Pancytopenia—Epirubicin—peripheral nervous system neoplasm	0.00186	0.00223	CcSEcCtD
Pralatrexate—Neutropenia—Epirubicin—peripheral nervous system neoplasm	0.00183	0.0022	CcSEcCtD
Pralatrexate—Asthenia—Alitretinoin—peripheral nervous system neoplasm	0.00183	0.00219	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Epirubicin—peripheral nervous system neoplasm	0.00182	0.00218	CcSEcCtD
Pralatrexate—TYMS—Vinorelbine—Vincristine—peripheral nervous system neoplasm	0.00181	0.0421	CbGdCrCtD
Pralatrexate—TYMS—Podofilox—Etoposide—peripheral nervous system neoplasm	0.00181	0.0421	CbGdCrCtD
Pralatrexate—Pruritus—Alitretinoin—peripheral nervous system neoplasm	0.0018	0.00216	CcSEcCtD
Pralatrexate—Dyspnoea—Etoposide—peripheral nervous system neoplasm	0.00177	0.00212	CcSEcCtD
Pralatrexate—Asthenia—Vincristine—peripheral nervous system neoplasm	0.00176	0.00211	CcSEcCtD
Pralatrexate—Vomiting—Dactinomycin—peripheral nervous system neoplasm	0.00175	0.00209	CcSEcCtD
Pralatrexate—Diarrhoea—Alitretinoin—peripheral nervous system neoplasm	0.00174	0.00209	CcSEcCtD
Pralatrexate—Rash—Dactinomycin—peripheral nervous system neoplasm	0.00173	0.00208	CcSEcCtD
Pralatrexate—SLC19A1—Disease—GNS—peripheral nervous system neoplasm	0.00173	0.0141	CbGpPWpGaD
Pralatrexate—Decreased appetite—Etoposide—peripheral nervous system neoplasm	0.00173	0.00207	CcSEcCtD
Pralatrexate—Pancytopenia—Doxorubicin—peripheral nervous system neoplasm	0.00172	0.00206	CcSEcCtD
Pralatrexate—Body temperature increased—Cisplatin—peripheral nervous system neoplasm	0.00172	0.00206	CcSEcCtD
Pralatrexate—Fatigue—Etoposide—peripheral nervous system neoplasm	0.00171	0.00205	CcSEcCtD
Pralatrexate—FPGS—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.00171	0.0139	CbGpPWpGaD
Pralatrexate—Constipation—Etoposide—peripheral nervous system neoplasm	0.0017	0.00204	CcSEcCtD
Pralatrexate—Neutropenia—Doxorubicin—peripheral nervous system neoplasm	0.0017	0.00203	CcSEcCtD
Pralatrexate—Upper respiratory tract infection—Doxorubicin—peripheral nervous system neoplasm	0.00169	0.00202	CcSEcCtD
Pralatrexate—Diarrhoea—Vincristine—peripheral nervous system neoplasm	0.00168	0.00201	CcSEcCtD
Pralatrexate—Epistaxis—Epirubicin—peripheral nervous system neoplasm	0.00165	0.00198	CcSEcCtD
Pralatrexate—Nausea—Dactinomycin—peripheral nervous system neoplasm	0.00163	0.00196	CcSEcCtD
Pralatrexate—Gastrointestinal pain—Etoposide—peripheral nervous system neoplasm	0.00163	0.00195	CcSEcCtD
Pralatrexate—Vomiting—Alitretinoin—peripheral nervous system neoplasm	0.00162	0.00194	CcSEcCtD
Pralatrexate—Rash—Alitretinoin—peripheral nervous system neoplasm	0.00161	0.00193	CcSEcCtD
Pralatrexate—Dermatitis—Alitretinoin—peripheral nervous system neoplasm	0.0016	0.00192	CcSEcCtD
Pralatrexate—Body temperature increased—Etoposide—peripheral nervous system neoplasm	0.00157	0.00188	CcSEcCtD
Pralatrexate—Abdominal pain—Etoposide—peripheral nervous system neoplasm	0.00157	0.00188	CcSEcCtD
Pralatrexate—Vomiting—Vincristine—peripheral nervous system neoplasm	0.00156	0.00187	CcSEcCtD
Pralatrexate—Asthenia—Cisplatin—peripheral nervous system neoplasm	0.00156	0.00187	CcSEcCtD
Pralatrexate—Rash—Vincristine—peripheral nervous system neoplasm	0.00155	0.00186	CcSEcCtD
Pralatrexate—Dermatitis—Vincristine—peripheral nervous system neoplasm	0.00155	0.00185	CcSEcCtD
Pralatrexate—Epistaxis—Doxorubicin—peripheral nervous system neoplasm	0.00152	0.00183	CcSEcCtD
Pralatrexate—Nausea—Alitretinoin—peripheral nervous system neoplasm	0.00151	0.00181	CcSEcCtD
Pralatrexate—Diarrhoea—Cisplatin—peripheral nervous system neoplasm	0.00148	0.00178	CcSEcCtD
Pralatrexate—FPGS—Disease—GNS—peripheral nervous system neoplasm	0.00147	0.012	CbGpPWpGaD
Pralatrexate—Nausea—Vincristine—peripheral nervous system neoplasm	0.00146	0.00175	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—GNS—peripheral nervous system neoplasm	0.00145	0.0118	CbGpPWpGaD
Pralatrexate—Asthenia—Etoposide—peripheral nervous system neoplasm	0.00143	0.00171	CcSEcCtD
Pralatrexate—DHFR—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.00142	0.0115	CbGpPWpGaD
Pralatrexate—Pruritus—Etoposide—peripheral nervous system neoplasm	0.00141	0.00169	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—NME1—peripheral nervous system neoplasm	0.00139	0.0113	CbGpPWpGaD
Pralatrexate—Vomiting—Cisplatin—peripheral nervous system neoplasm	0.00138	0.00165	CcSEcCtD
Pralatrexate—Rash—Cisplatin—peripheral nervous system neoplasm	0.00137	0.00164	CcSEcCtD
Pralatrexate—Dermatitis—Cisplatin—peripheral nervous system neoplasm	0.00137	0.00164	CcSEcCtD
Pralatrexate—Diarrhoea—Etoposide—peripheral nervous system neoplasm	0.00136	0.00163	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.00135	0.011	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—COX2—peripheral nervous system neoplasm	0.00134	0.0109	CbGpPWpGaD
Pralatrexate—Back pain—Epirubicin—peripheral nervous system neoplasm	0.00132	0.00158	CcSEcCtD
Pralatrexate—Nausea—Cisplatin—peripheral nervous system neoplasm	0.00129	0.00155	CcSEcCtD
Pralatrexate—Vomiting—Etoposide—peripheral nervous system neoplasm	0.00126	0.00152	CcSEcCtD
Pralatrexate—Anaemia—Epirubicin—peripheral nervous system neoplasm	0.00126	0.00151	CcSEcCtD
Pralatrexate—Rash—Etoposide—peripheral nervous system neoplasm	0.00125	0.0015	CcSEcCtD
Pralatrexate—Dermatitis—Etoposide—peripheral nervous system neoplasm	0.00125	0.0015	CcSEcCtD
Pralatrexate—TYMS—Vinblastine—Vincristine—peripheral nervous system neoplasm	0.00125	0.029	CbGdCrCtD
Pralatrexate—TYMS—Fluoropyrimidine Activity—TP53—peripheral nervous system neoplasm	0.00124	0.0101	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GNS—peripheral nervous system neoplasm	0.00123	0.01	CbGpPWpGaD
Pralatrexate—Leukopenia—Epirubicin—peripheral nervous system neoplasm	0.00122	0.00147	CcSEcCtD
Pralatrexate—Back pain—Doxorubicin—peripheral nervous system neoplasm	0.00122	0.00147	CcSEcCtD
Pralatrexate—SLC19A1—Disease—PPP3R1—peripheral nervous system neoplasm	0.00121	0.00986	CbGpPWpGaD
Pralatrexate—Cough—Epirubicin—peripheral nervous system neoplasm	0.00119	0.00143	CcSEcCtD
Pralatrexate—FPGS—Metabolism—NME1—peripheral nervous system neoplasm	0.00118	0.00962	CbGpPWpGaD
Pralatrexate—Nausea—Etoposide—peripheral nervous system neoplasm	0.00118	0.00142	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—CDKN2A—peripheral nervous system neoplasm	0.00118	0.00958	CbGpPWpGaD
Pralatrexate—Anaemia—Doxorubicin—peripheral nervous system neoplasm	0.00117	0.0014	CcSEcCtD
Pralatrexate—FPGS—Metabolism—COX2—peripheral nervous system neoplasm	0.00114	0.00926	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CHEK2—peripheral nervous system neoplasm	0.00114	0.00924	CbGpPWpGaD
Pralatrexate—Leukopenia—Doxorubicin—peripheral nervous system neoplasm	0.00113	0.00136	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—TH—peripheral nervous system neoplasm	0.00112	0.00909	CbGpPWpGaD
Pralatrexate—Oedema—Epirubicin—peripheral nervous system neoplasm	0.00111	0.00134	CcSEcCtD
Pralatrexate—Cough—Doxorubicin—peripheral nervous system neoplasm	0.0011	0.00132	CcSEcCtD
Pralatrexate—Thrombocytopenia—Epirubicin—peripheral nervous system neoplasm	0.00109	0.00131	CcSEcCtD
Pralatrexate—Tachycardia—Epirubicin—peripheral nervous system neoplasm	0.00109	0.0013	CcSEcCtD
Pralatrexate—Anorexia—Epirubicin—peripheral nervous system neoplasm	0.00106	0.00127	CcSEcCtD
Pralatrexate—DHFR—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00105	0.00858	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ENO2—peripheral nervous system neoplasm	0.00105	0.00854	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—NTRK1—peripheral nervous system neoplasm	0.00104	0.00842	CbGpPWpGaD
Pralatrexate—Oedema—Doxorubicin—peripheral nervous system neoplasm	0.00103	0.00124	CcSEcCtD
Pralatrexate—FPGS—Disease—PPP3R1—peripheral nervous system neoplasm	0.00103	0.00838	CbGpPWpGaD
Pralatrexate—Thrombocytopenia—Doxorubicin—peripheral nervous system neoplasm	0.00101	0.00121	CcSEcCtD
Pralatrexate—Tachycardia—Doxorubicin—peripheral nervous system neoplasm	0.00101	0.00121	CcSEcCtD
Pralatrexate—TYMS—Circadian rythm related genes—NTRK1—peripheral nervous system neoplasm	0.000994	0.00809	CbGpPWpGaD
Pralatrexate—Dyspnoea—Epirubicin—peripheral nervous system neoplasm	0.000994	0.00119	CcSEcCtD
Pralatrexate—Anorexia—Doxorubicin—peripheral nervous system neoplasm	0.000983	0.00118	CcSEcCtD
Pralatrexate—Decreased appetite—Epirubicin—peripheral nervous system neoplasm	0.000969	0.00116	CcSEcCtD
Pralatrexate—Fatigue—Epirubicin—peripheral nervous system neoplasm	0.000961	0.00115	CcSEcCtD
Pralatrexate—Constipation—Epirubicin—peripheral nervous system neoplasm	0.000953	0.00114	CcSEcCtD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—BDNF—peripheral nervous system neoplasm	0.000948	0.00771	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ABCB1—peripheral nervous system neoplasm	0.000932	0.00758	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—PPIP5K2—peripheral nervous system neoplasm	0.00092	0.00749	CbGpPWpGaD
Pralatrexate—Dyspnoea—Doxorubicin—peripheral nervous system neoplasm	0.000919	0.0011	CcSEcCtD
Pralatrexate—DHFR—E2F transcription factor network—MYC—peripheral nervous system neoplasm	0.000914	0.00744	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Epirubicin—peripheral nervous system neoplasm	0.000911	0.00109	CcSEcCtD
Pralatrexate—Decreased appetite—Doxorubicin—peripheral nervous system neoplasm	0.000896	0.00107	CcSEcCtD
Pralatrexate—FPGS—Disease—ENO2—peripheral nervous system neoplasm	0.000892	0.00726	CbGpPWpGaD
Pralatrexate—Fatigue—Doxorubicin—peripheral nervous system neoplasm	0.000889	0.00107	CcSEcCtD
Pralatrexate—Constipation—Doxorubicin—peripheral nervous system neoplasm	0.000882	0.00106	CcSEcCtD
Pralatrexate—Body temperature increased—Epirubicin—peripheral nervous system neoplasm	0.000881	0.00106	CcSEcCtD
Pralatrexate—Abdominal pain—Epirubicin—peripheral nervous system neoplasm	0.000881	0.00106	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—ENO2—peripheral nervous system neoplasm	0.000879	0.00715	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—SLC2A1—peripheral nervous system neoplasm	0.000846	0.00688	CbGpPWpGaD
Pralatrexate—Gastrointestinal pain—Doxorubicin—peripheral nervous system neoplasm	0.000843	0.00101	CcSEcCtD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—CDKN2A—peripheral nervous system neoplasm	0.000825	0.00672	CbGpPWpGaD
Pralatrexate—Body temperature increased—Doxorubicin—peripheral nervous system neoplasm	0.000815	0.000977	CcSEcCtD
Pralatrexate—Abdominal pain—Doxorubicin—peripheral nervous system neoplasm	0.000815	0.000977	CcSEcCtD
Pralatrexate—DHFR—Folate Metabolism—TP53—peripheral nervous system neoplasm	0.000814	0.00662	CbGpPWpGaD
Pralatrexate—Asthenia—Epirubicin—peripheral nervous system neoplasm	0.0008	0.000959	CcSEcCtD
Pralatrexate—TYMS—E2F transcription factor network—MYC—peripheral nervous system neoplasm	0.000798	0.00649	CbGpPWpGaD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—MYC—peripheral nervous system neoplasm	0.000795	0.00647	CbGpPWpGaD
Pralatrexate—Pruritus—Epirubicin—peripheral nervous system neoplasm	0.000788	0.000945	CcSEcCtD
Pralatrexate—Diarrhoea—Epirubicin—peripheral nervous system neoplasm	0.000762	0.000914	CcSEcCtD
Pralatrexate—FPGS—Metabolism—ENO2—peripheral nervous system neoplasm	0.000747	0.00608	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—BCHE—peripheral nervous system neoplasm	0.000742	0.00604	CbGpPWpGaD
Pralatrexate—Asthenia—Doxorubicin—peripheral nervous system neoplasm	0.00074	0.000887	CcSEcCtD
Pralatrexate—Pruritus—Doxorubicin—peripheral nervous system neoplasm	0.00073	0.000875	CcSEcCtD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—CDKN2A—peripheral nervous system neoplasm	0.00072	0.00586	CbGpPWpGaD
Pralatrexate—FPGS—Disease—SLC2A1—peripheral nervous system neoplasm	0.000719	0.00585	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000713	0.0058	CbGpPWpGaD
Pralatrexate—Vomiting—Epirubicin—peripheral nervous system neoplasm	0.000709	0.000849	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000708	0.00576	CbGpPWpGaD
Pralatrexate—Diarrhoea—Doxorubicin—peripheral nervous system neoplasm	0.000706	0.000846	CcSEcCtD
Pralatrexate—DHFR—Cell Cycle, Mitotic—AURKA—peripheral nervous system neoplasm	0.000704	0.00573	CbGpPWpGaD
Pralatrexate—Rash—Epirubicin—peripheral nervous system neoplasm	0.000703	0.000842	CcSEcCtD
Pralatrexate—Dermatitis—Epirubicin—peripheral nervous system neoplasm	0.000702	0.000842	CcSEcCtD
Pralatrexate—SLC19A1—Metabolism—TH—peripheral nervous system neoplasm	0.000698	0.00568	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—MYC—peripheral nervous system neoplasm	0.000693	0.00564	CbGpPWpGaD
Pralatrexate—DHFR—G1/S Transition—MYC—peripheral nervous system neoplasm	0.000664	0.0054	CbGpPWpGaD
Pralatrexate—Nausea—Epirubicin—peripheral nervous system neoplasm	0.000662	0.000794	CcSEcCtD
Pralatrexate—Vomiting—Doxorubicin—peripheral nervous system neoplasm	0.000656	0.000786	CcSEcCtD
Pralatrexate—DHFR—Retinoblastoma (RB) in Cancer—TP53—peripheral nervous system neoplasm	0.000653	0.00531	CbGpPWpGaD
Pralatrexate—Rash—Doxorubicin—peripheral nervous system neoplasm	0.00065	0.000779	CcSEcCtD
Pralatrexate—Dermatitis—Doxorubicin—peripheral nervous system neoplasm	0.00065	0.000779	CcSEcCtD
Pralatrexate—FPGS—Metabolism—BCHE—peripheral nervous system neoplasm	0.000631	0.00514	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—AURKA—peripheral nervous system neoplasm	0.00063	0.00513	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—HSD17B12—peripheral nervous system neoplasm	0.000622	0.00506	CbGpPWpGaD
Pralatrexate—DHFR—Disease—GNS—peripheral nervous system neoplasm	0.000615	0.00501	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—AURKA—peripheral nervous system neoplasm	0.000615	0.005	CbGpPWpGaD
Pralatrexate—Nausea—Doxorubicin—peripheral nervous system neoplasm	0.000612	0.000734	CcSEcCtD
Pralatrexate—FPGS—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000602	0.0049	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—TH—peripheral nervous system neoplasm	0.000594	0.00483	CbGpPWpGaD
Pralatrexate—TYMS—G1/S Transition—MYC—peripheral nervous system neoplasm	0.000579	0.00471	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—GNAS—peripheral nervous system neoplasm	0.00057	0.00464	CbGpPWpGaD
Pralatrexate—TYMS—Retinoblastoma (RB) in Cancer—TP53—peripheral nervous system neoplasm	0.000569	0.00463	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CHEK2—peripheral nervous system neoplasm	0.000563	0.00458	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000559	0.00455	CbGpPWpGaD
Pralatrexate—DHFR—Mitotic G1-G1/S phases—MYC—peripheral nervous system neoplasm	0.000559	0.00455	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—AURKA—peripheral nervous system neoplasm	0.00055	0.00447	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—ERBB2—peripheral nervous system neoplasm	0.000522	0.00425	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GNS—peripheral nervous system neoplasm	0.000515	0.00419	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—NME1—peripheral nervous system neoplasm	0.000494	0.00402	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CHEK2—peripheral nervous system neoplasm	0.000491	0.004	CbGpPWpGaD
Pralatrexate—TYMS—Mitotic G1-G1/S phases—MYC—peripheral nervous system neoplasm	0.000488	0.00397	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—GNAS—peripheral nervous system neoplasm	0.000485	0.00394	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000475	0.00387	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—COX2—peripheral nervous system neoplasm	0.000475	0.00387	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—CASP3—peripheral nervous system neoplasm	0.000473	0.00385	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—PTPN11—peripheral nervous system neoplasm	0.000473	0.00385	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—BIRC5—peripheral nervous system neoplasm	0.000457	0.00372	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GNS—peripheral nervous system neoplasm	0.000449	0.00366	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—NME1—peripheral nervous system neoplasm	0.000431	0.00351	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PPP3R1—peripheral nervous system neoplasm	0.00043	0.0035	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—COX2—peripheral nervous system neoplasm	0.000415	0.00338	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—BIRC5—peripheral nervous system neoplasm	0.000408	0.00332	CbGpPWpGaD
Pralatrexate—FPGS—Disease—PTPN11—peripheral nervous system neoplasm	0.000402	0.00327	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—BIRC5—peripheral nervous system neoplasm	0.000398	0.00324	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—ERBB2—peripheral nervous system neoplasm	0.000374	0.00304	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ENO2—peripheral nervous system neoplasm	0.000373	0.00303	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—MYC—peripheral nervous system neoplasm	0.00037	0.00301	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—BIRC5—peripheral nervous system neoplasm	0.000356	0.0029	CbGpPWpGaD
Pralatrexate—FPGS—Disease—ERBB2—peripheral nervous system neoplasm	0.000318	0.00259	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ENO2—peripheral nervous system neoplasm	0.000312	0.00254	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—TP53—peripheral nervous system neoplasm	0.000304	0.00247	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—CDKN2A—peripheral nervous system neoplasm	0.000303	0.00246	CbGpPWpGaD
Pralatrexate—DHFR—Disease—SLC2A1—peripheral nervous system neoplasm	0.0003	0.00244	CbGpPWpGaD
Pralatrexate—TYMS—Circadian rythm related genes—TP53—peripheral nervous system neoplasm	0.000291	0.00237	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—NRAS—peripheral nervous system neoplasm	0.000284	0.00231	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ENO2—peripheral nervous system neoplasm	0.000272	0.00222	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—CDKN2A—peripheral nervous system neoplasm	0.000271	0.0022	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—MYC—peripheral nervous system neoplasm	0.000265	0.00216	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—CDKN2A—peripheral nervous system neoplasm	0.000264	0.00215	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—BCHE—peripheral nervous system neoplasm	0.000264	0.00215	CbGpPWpGaD
Pralatrexate—TYMS—Integrated Pancreatic Cancer Pathway—AKT1—peripheral nervous system neoplasm	0.000256	0.00209	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.000252	0.00205	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—TH—peripheral nervous system neoplasm	0.000248	0.00202	CbGpPWpGaD
Pralatrexate—FPGS—Disease—NRAS—peripheral nervous system neoplasm	0.000242	0.00197	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—CDKN2A—peripheral nervous system neoplasm	0.000236	0.00192	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—BCHE—peripheral nervous system neoplasm	0.00023	0.00187	CbGpPWpGaD
Pralatrexate—FPGS—Disease—MYC—peripheral nervous system neoplasm	0.000225	0.00183	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—SLC2A1—peripheral nervous system neoplasm	0.00022	0.00179	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—TH—peripheral nervous system neoplasm	0.000216	0.00176	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—HRAS—peripheral nervous system neoplasm	0.000208	0.00169	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	0.000205	0.00167	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—GNAS—peripheral nervous system neoplasm	0.000202	0.00165	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000199	0.00162	CbGpPWpGaD
Pralatrexate—SLC19A1—Disease—AKT1—peripheral nervous system neoplasm	0.000184	0.00149	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—MYC—peripheral nervous system neoplasm	0.000183	0.00149	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle, Mitotic—MYC—peripheral nervous system neoplasm	0.000179	0.00146	CbGpPWpGaD
Pralatrexate—FPGS—Disease—HRAS—peripheral nervous system neoplasm	0.000177	0.00144	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—GNAS—peripheral nervous system neoplasm	0.000177	0.00144	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—ABCB1—peripheral nervous system neoplasm	0.000173	0.00141	CbGpPWpGaD
Pralatrexate—DHFR—Disease—PTPN11—peripheral nervous system neoplasm	0.000168	0.00137	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—MYC—peripheral nervous system neoplasm	0.00016	0.0013	CbGpPWpGaD
Pralatrexate—FPGS—Disease—AKT1—peripheral nervous system neoplasm	0.000156	0.00127	CbGpPWpGaD
Pralatrexate—SLC19A1—Metabolism—AKT1—peripheral nervous system neoplasm	0.000154	0.00125	CbGpPWpGaD
Pralatrexate—DHFR—Cell Cycle—TP53—peripheral nervous system neoplasm	0.000151	0.00123	CbGpPWpGaD
Pralatrexate—DHFR—Disease—ERBB2—peripheral nervous system neoplasm	0.000133	0.00108	CbGpPWpGaD
Pralatrexate—TYMS—Cell Cycle—TP53—peripheral nervous system neoplasm	0.000131	0.00107	CbGpPWpGaD
Pralatrexate—FPGS—Metabolism—AKT1—peripheral nervous system neoplasm	0.000131	0.00106	CbGpPWpGaD
Pralatrexate—DHFR—Disease—NRAS—peripheral nervous system neoplasm	0.000101	0.000822	CbGpPWpGaD
Pralatrexate—DHFR—Disease—MYC—peripheral nervous system neoplasm	9.41e-05	0.000766	CbGpPWpGaD
Pralatrexate—DHFR—Disease—HRAS—peripheral nervous system neoplasm	7.39e-05	0.000601	CbGpPWpGaD
Pralatrexate—DHFR—Disease—AKT1—peripheral nervous system neoplasm	6.52e-05	0.000531	CbGpPWpGaD
Pralatrexate—DHFR—Metabolism—AKT1—peripheral nervous system neoplasm	5.46e-05	0.000445	CbGpPWpGaD
Pralatrexate—TYMS—Metabolism—AKT1—peripheral nervous system neoplasm	4.77e-05	0.000388	CbGpPWpGaD
